AbbVie Receives Two New FDA's Breakthrough Therapy Designations For Telisotuzumab Adizutecan In Colorectal Cancer, Non-Small Cell Lung Cancer

AbbVie (NYSE: ABBV) has received two Breakthrough Therapy Designations from the U.S. FDA for its drug telisotuzumab adizutecan (Temab-A; ABBV-400) targeting colorectal cancer and non-small cell lung cancer. This designation is intended to expedite the development and review of therapies that show substantial improvement over existing treatments.